Liposomal imatinib–mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer
- 23 November 2010
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 71 (1) , 81-90
Abstract
BACKGROUND: Mitoxantrone plus prednisone is a palliative treatment for hormone‐refractory prostate cancer (HRPC) but without survival benefit. Imatinib has shown activity against HRPC but only in the preclinical setting. Our previous in vitro cytotoxicity screening study established that their free combination act additively to inhibit proliferation of PC‐3 cells. We aim to develop a liposomal imatinib–mitoxantrone (LIM) formulation with improved in vivo therapeutic activity.METHODS: Imatinib and mitoxantrone were simultaneously co‐loaded into DSPC/Chol liposomes by means of a (NH4)2SO4‐generated proton gradient method. The optimized formulation was characterized in terms of mean size diameter, loading parameters and drug retention in human serum. In vivo antitumor activity of developed LIM formulation was evaluated in a nude mice bearing subcutaneous PC‐3 xenograft model.RESULTS: LIM formulation exhibited maximal encapsulation efficiency (>95%) and enhanced drug retention for both drugs. Additionally, this LIM formulation, administered at a low mitoxantrone dose (0.5 mg/kg), showed a tumor inhibition activity (TGI = 66.7% and 4.0‐fold tumor volume increase) slightly superior to that of liposomal mitoxantrone (LM) at 2 mg/kg (TGI = 53.0% and 4.2‐fold volume increase). Therefore, therapeutic activity of mitoxantrone was significantly improved by co‐loading with imatinib since a four times lower dose was needed to achieve an equivalent growth inhibition effect.CONCLUSIONS: The loading parameters and drug retention properties of our LIM formulation, combined with its in vivo antitumor activity, make this formulation an excellent strategy to improve the therapeutic index of mitoxantrone and a promising candidate for clinical development in prostate cancer therapy. Prostate 71: 81–90, 2011.Keywords
This publication has 47 references indexed in Scilit:
- Liposomal gemcitabine (GemLip)—efficient drug against hormone‐refractory Du145 and PC‐3 prostate cancer xenograftsThe Prostate, 2009
- Tumour-targeted nanomedicines: principles and practiceBritish Journal of Cancer, 2008
- Treatment with imatinib improves drug delivery and efficacy in NSCLC xenograftsBritish Journal of Cancer, 2007
- Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicinApoptosis, 2006
- Clinical Pharmacokinetics of ImatinibClinical Pharmacokinetics, 2005
- Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer modelsThe Prostate, 2003
- Pharmacology of imatinib (STI571)European Journal of Cancer, 2002
- MitoxantroneDrugs & Aging, 1997
- Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administrationEuropean Journal of Drug Metabolism and Pharmacokinetics, 1990
- Vesicles of variable sizes produced by a rapid extrusion procedureBiochimica et Biophysica Acta (BBA) - Biomembranes, 1986